

PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/671,074
Filing Date	September 25, 2003
First Named Inventor	Kenneth W. Dobie
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	AMGN0001-101 (A-829A)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
KC	AA	ANDERSON, et al., "Genes, chromosomes and rhabdomyosarcoma," Genes Chromosomes Cancer (1999) 26:275-285.	
	AB	ANDERSON, et al., "PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma," Am. J. Pathol. (2001) 158:1089-1098.	
	AC	ANDERSON, et al., "Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3," Proc. Natl. Acad. Sci. USA (2001) 98:1589-1594.	
	AD	BENNICELLI, et al., "Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma," Proc. Natl. Acad. Sci. USA (1996) 93:5455-5459.	
	AE	BERNASCONI, et al., "Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins," Proc. Natl. Acad. Sci. USA (1996) 93:13164-13169.	
	AF	DAVIS, et al., "Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma," Proc. Natl. Acad. Sci. USA (1997) 94:8047-8051.	
	AG	DAVIS, et al., "Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma," Human Mol. Genet. (1995) 4:2355-2362.	
	AH	DAVIS, et al., "Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma," Cancer Res. (1994) 54:2869-2872.	
	AI	DEL PESO et al., "Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase, Akt," Oncogene (1999) 18:7328-7333.	
	AJ	DURHAM, et al., "FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter," Endocrinology (1999) 140:3140-3146.	
✓	AK	EPSTEIN, et al., "Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor," Mol. Cell. Biol. (1998) 18:4118-4130.	


Examiner
SignatureDate
Considered

1/17/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	10/671,074
Filing Date	September 25, 2003
First Named Inventor	Kenneth W. Dobie
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	AMGN0001-101 (A-829A)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KC	AL	GAJIWALA, et al., "Winged helix proteins," Curr. Opin. Struct. Biol. (2000) 10:110-116.	
	AM	GALILI, et al., "Fusion of a fork head domain gene to PAX3 in the solid tumor alveolar rhabdomyosarcoma," Nat. Genet. (1993) 5:230-235.	
	AN	GUO, et al., "Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin-like growth factor -binding protein-1 promoter activity through a conserved insulin response sequence," J. Biol. Chem. (1999) 274:17184-17192.	
	AO	MARGUE, et al., "Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR," Oncogene (2000) 19:2921-2929.	
	AP	NAKAE, et al., "The forkhead transcription factor Foxo1 (FKHR) confers insulin sensitivity onto glucose-6-phosphatase expression," J. Clin. Invest. (2001) 108:1359-1367.	
	AQ	SCHEIDLER, et al., "The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcomatransforms fibroblasts in culture," Proc. Natl. Acad. Sci. USA (1996) 93:9805-9809.	
	AR	TANG, et al., "Negative regulation of the forkhead transcription factor by FKHR by Akt," J. Biol. Chem. (1999) 274:16741-16746.	

Examiner Signature		Date Considered	1/17/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/671,074
Filing Date	September 25, 2003
First Named Inventor	Kenneth W. Dobie
Art Unit	1614
Examiner Name	Moise, Emmanuel Lionel
Attorney Docket Number	HTS-0008US.P1

[illegible][illegible]

**Examiner
Signature**

Date Considered

1/17/06

*EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

WFO Standard SI. To be possible. Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

Complete if Known

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Application Number	10/671,074
Filing Date	September 25, 2003
First Named Inventor	Kenneth W. Dobie
Art Unit	1614
Examiner Name	Moise, Emmanuel Lionel
Attorney Docket Number	HTS-0008US.P1

[illegible]

**Examiner
Signature**

Date
Considered

1/17/06

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.